{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T07:16:02Z","timestamp":1774768562977,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007514","name":"Universit\u00e0 di Pisa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007514","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2017NR7W5K"],"award-info":[{"award-number":["2017NR7W5K"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.clgc.2024.102147","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T17:25:40Z","timestamp":1719509140000},"page":"102147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal Cancer"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7343-6161","authenticated-orcid":false,"given":"Marzia","family":"Del Re","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4414-8934","authenticated-orcid":false,"given":"Stefania","family":"Crucitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Brighi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2183-8892","authenticated-orcid":false,"given":"Stefania","family":"Kinspergher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1165-1776","authenticated-orcid":false,"given":"Chiara","family":"Mercinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7743-741X","authenticated-orcid":false,"given":"Mimma","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6921-714X","authenticated-orcid":false,"given":"Vincenza","family":"Conteduca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0546-6304","authenticated-orcid":false,"given":"Sara Elena","family":"Rebuzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Beninato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Venturi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Doni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Verzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Landriscina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6864-7171","authenticated-orcid":false,"given":"Fiorella","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7968-2531","authenticated-orcid":false,"given":"Orazio","family":"Caffo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Fogli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clgc.2024.102147_bib0001","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/clpt.2012.73","article-title":"Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?","volume":"92","author":"Budha","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.clgc.2024.102147_bib0002","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.clgc.2017.05.019","article-title":"Proton pump inhibitors and survival outcomes in patients with metastatic renal cell carcinoma","volume":"15","author":"Lalani","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2024.102147_bib0003","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/MCG.0000000000001375","article-title":"Association of gastric acid suppression and sorafenib efficacy in advanced hepatocellular carcinoma","volume":"55","author":"Razak","year":"2021","journal-title":"J Clin Gastroenterol"},{"issue":"9","key":"10.1016\/j.clgc.2024.102147_bib0004","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s40262-017-0510-z","article-title":"Clinical pharmacokinetics and pharmacodynamics of pazopanib: towards optimized dosing","volume":"56","author":"Verheijen","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1016\/j.clgc.2024.102147_bib0005","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1002\/ijc.33469","article-title":"The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure","volume":"148","author":"Krens","year":"2021","journal-title":"Int J Cancer"},{"issue":"9","key":"10.1016\/j.clgc.2024.102147_bib0006","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00228-020-02902-3","article-title":"Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma","volume":"76","author":"Van De Sijpe","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.clgc.2024.102147_bib0007","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1634\/theoncologist.2017-0578","article-title":"Effect of concomitant pH-elevating medications with pazopanib on progression-free survival and overall survival in patients with metastatic renal cell carcinoma","volume":"23","author":"McAlister","year":"2018","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.clgc.2024.102147_bib0008","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/1078155214527145","article-title":"Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer?","volume":"21","author":"Ha","year":"2015","journal-title":"J Oncol Pharm Pract"},{"issue":"7","key":"10.1016\/j.clgc.2024.102147_bib0009","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/cncr.31917","article-title":"The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer","volume":"125","author":"Sharma","year":"2019","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.clgc.2024.102147_bib0010","doi-asserted-by":"crossref","first-page":"7805","DOI":"10.3390\/molecules28237805","article-title":"Solubility and thermodynamics data of cabozantinib malate in various aqueous solutions of dimethyl sulfoxide at different temperatures","volume":"28","author":"Shakeel","year":"2023","journal-title":"Molecules"},{"issue":"11","key":"10.1016\/j.clgc.2024.102147_bib0011","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/jcph.526","article-title":"Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects","volume":"55","author":"Nguyen","year":"2015","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102147_bib0012","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/onco.13711","article-title":"The effect of concomitant proton pump inhibitor and cabozantinib on the outcomes of patients with metastatic renal cell carcinoma","volume":"26","author":"Rassy","year":"2021","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.clgc.2024.102147_bib0013","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/cancers12040998","article-title":"Impact of use of gastric-acid suppressants and oral anti-cancer agents on survival outcomes: a systematic review and meta-analysis","volume":"12","author":"Indini","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.clgc.2024.102147_bib0014","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s00280-013-2164-3","article-title":"Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors","volume":"71","author":"Tan","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.clgc.2024.102147_bib0015","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00280-017-3463-x","article-title":"Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization","volume":"80","author":"Verheijen","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.clgc.2024.102147_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100312","article-title":"Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics\/pharmacodynamics study","volume":"6","author":"Cerbone","year":"2021","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.clgc.2024.102147_bib0017","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clgc.2015.01.007","article-title":"Assessment of sunitinib-induced toxicities and clinical outcomes based on therapeutic drug monitoring of sunitinib for patients with renal cell carcinoma","volume":"13","author":"Noda","year":"2015","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2024.102147_bib0018","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clgc.2024.102147_bib0019","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2024.102147_bib0020","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/jjco\/hyp146","article-title":"A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety","volume":"40","author":"Uemura","year":"2010","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2024.102147_bib0021","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","article-title":"Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis","volume":"66","author":"Houk","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"10.1016\/j.clgc.2024.102147_bib0022","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/bjc.2014.503","article-title":"Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma","volume":"111","author":"Suttle","year":"2014","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.clgc.2024.102147_bib0023","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1158\/1078-0432.CCR-18-2748","article-title":"Impact of concomitant administration of gastric acid-suppressive agents and pazopanib on outcomes in soft-tissue sarcoma patients treated within the EORTC 62043\/62072 trials","volume":"25","author":"Mir","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.clgc.2024.102147_bib0024","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/cts.12648","article-title":"Effect of acid-suppressive strategies on pazopanib efficacy in patients with soft-tissue sarcoma","volume":"12","author":"Pisano","year":"2019","journal-title":"Clin Transl Sci"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T06:57:08Z","timestamp":1738565828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324001186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1558767324001186"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102147","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102147","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102147"}}